Bavarian Nordic, a Kvistgaard, Denmark-based biotechnology company, has partnered with SGS, a contract analytical laboratory, to develop a new respiratory syncytial virus (RSV) challenge strain.

SGS says the partnership will assist with advancing a universal vaccine candidate designed to induce protective immune responses against both subtypes (A&B) of RSV.

The project will build upon the results of Phase II trials undertaken by Bavarian Nordic and will include a human challenge study, which will be carried out at SGS’ clinical pharmacology unit in Antwerp, Belgium, using the new RSV challenge strain, once it has been fully developed and validated.

Source: SGS